scPharmaceuticals Inc. (SCPH) Share-based Payment Arrangement, Expense USD 2017 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
scPharmaceuticals Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2017 to 2024.
  • scPharmaceuticals Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $1.44 M, a 46.9% increase year-over-year.
  • scPharmaceuticals Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $5.32 M, a 67.1% increase year-over-year.
  • scPharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2023 was $4.86 M, a 71.1% increase from 2022.
  • scPharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2.84 M, a 19.9% increase from 2021.
  • scPharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2021 was $2.37 M, a 18.3% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $5.32 M $1.44 M +$460 K +46.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $4.86 M $1.42 M +$679 K +92.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-13
Q3 2023 $4.18 M $1.28 M +$496 K +63.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $3.68 M $1.18 M +$499 K +73.4% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $3.18 M $980 K +$344 K +54.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $2.84 M $737 K +$100 K +15.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-13
Q3 2022 $2.74 M $785 K +$166 K +26.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $2.57 M $680 K +$91 K +15.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $2.48 M $636 K +$115 K +22.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $2.37 M $637 K +$510 K +402% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-22
Q3 2021 $1.86 M $619 K -$125 K -16.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $1.98 M $589 K -$32 K -5.15% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $2.01 M $521 K +$13 K +2.56% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $2 M $127 K -$308 K -70.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-22
Q3 2020 $2.31 M $744 K +$411 K +123% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $1.9 M $621 K +$295 K +90.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 $1.6 M $508 K +$153 K +43.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q4 2019 $1.45 M $435 K -$18 K -3.97% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-23
Q3 2019 $1.47 M $333 K -$230 K -40.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 $1.7 M $326 K -$171 K -34.4% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 $1.87 M $355 K -$267 K -42.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 $2.14 M $453 K +$76 K +20.2% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-24
Q3 2018 $2.06 M $563 K +$329 K +141% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $1.73 M $497 K +$269 K +118% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $1.46 M $622 K +$514 K +476% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 $947 K $377 K Oct 1, 2017 Dec 31, 2017 10-K 2019-03-21
Q3 2017 $234 K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 $228 K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 $108 K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.